Late recurrence of a malignant hypoglycemia‑inducing pelvic solitary fibrous tumor secreting high‑molecular‑weight insulin‑like growth factor‑II: A case report with protein analysis by ISHIHARA Hiroki et al.
Late recurrence of a malignant
hypoglycemia?inducing pelvic solitary fibrous
tumor secreting high?molecular?weight
insulin?like growth factor?II: A case report
with protein analysis
journal or
publication title
Oncology letters
volume 12
number 1
page range 479-484
year 2016
URL http://hdl.handle.net/10470/00031697
doi: 10.3892/ol.2016.4665(https://doi.org/10.3892/ol.2016.4665)
ONCOLOGY LETTERS  12:  479-484,  2016
Abstract. The present study reports a case of recurrent 
malignant pelvic solitary fibrous tumor (SFT) that induced 
non-islet cell tumor hypoglycemia via high-molecular-weight 
insulin-like growth factor-II in a 72-year-old male patient. The 
tumor recurred ~12 years after the complete resection of the 
original mass. The recurrent tumor, which had directly invaded 
the left ureter and perirectal fat tissue, could not be completely 
excised due to its fragility and adhesiveness. At 13 days 
post-surgery, the patient presented with rectal perforation, 
and an urgent rectal resection and colostomy was performed. 
Neither recurrence of the tumor nor hypoglycemic symptoms 
were observed 9 months after the surgery. High molecular 
weight insulin-like growth factor-II was detected in the serum 
and tumor specimens by western blot analysis and immuno-
histochemistry. The present case report suggests that certain 
SFTs can relapse even ≥10 years after a presumed complete 
resection of the primary tumor, and that performing a safe and 
complete resection of these tumors can be challenging, due 
to their adhesiveness or physical presentation; therefore, the 
indications for surgery should be considered with caution.
Introduction
Solitary fibrous tumors (SFTs) are rare, non‑functional, and 
generally benign mesenchymal tumors, with an estimated 
age‑standardized incidence of 1.4 per million population (1,2). 
Despite the fact that SFTs are mainly intrathoracic (1), on 
rare occasions they can appear in extrapleural sites, such as 
the retroperitoneal (3) and pelvic regions (4). In total, 10‑20% 
of SFTs are classified as malignant, and eventually lead to 
mortality (1). Previous studies have reported the association 
of malignant SFTs with non‑islet cell tumor hypoglycemia 
(NICTH) due to the secretion of insulin‑like growth factor 
(IGF)‑II by the tumor cells (1,3,5,6). Furthermore, certain 
SFTs have been shown to recur >10 years after the resection of 
the original tumor, regardless of whether the original tumors 
were benign or malignant (7).
The present study reports a case of malignant pelvic SFT 
with NICTH due to IGF‑II secretion in a 72‑year‑old male 
patient. The tumor recurred ~12 years after the first surgery, 
despite the presumed complete excision of the original tumor, 
which is a rare occurrence. The tumor was evaluated using 
several imaging tests, as well as pathological, immunohisto-
chemical and western blot analyses. A second surgery was 
performed for the excision of the recurrent tumor, which may 
have been incomplete due to the tumor's strong adhesiveness 
and anatomical features. A postoperative computed tomog-
raphy (CT) scan showed no evidence of either recurrence or 
metastasis, and, at the time of writing, the patient remained 
asymptomatic at 9 months post-surgery.
Case report
A 72-year-old male patient with intermittent loss of conscious-
ness was admitted to another hospital. Laboratory data 
revealed a reduced blood glucose level of 28 mg/dl (normal 
level, 75‑109 mg/dl), and the patient was deemed to be in a 
hypoglycemic coma. Subsequent hypoglycemic attacks 
occurred frequently, necessitating a more extensive exami-
nation. Hormonal tests revealed elevated levels of serum 
IGF‑II by western blotting (molecular weight, 20.9 kDa). 
Other markers were found to be suppressed, including 
serum C‑peptide (0.2 ng/ml; normal level, 1.1-3.3 ng/ml), 
IGF‑I (52.0 ng/ml; normal level, 63.0-206.0 ng/ml), growth 
hormone (GH) (<0.05 ng/ml; normal level, <0.42 ng/ml) and 
immunoreactive insulin (<0.1 µU/ml; normal level, <0.4 µU/ml). 
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Abdominal CT and magnetic resonance imaging (MRI) 
scans revealed a pelvic tumor measuring ~7 cm in diameter. 
On the basis of these findings, an IGF‑producing tumor was 
suspected. Primary surgery was performed on May 2002, 
and the tumor was completely excised. Microscopically, the 
tumor was diagnosed as an IGF‑II‑producing SFT, based on 
its positive immunoreactivity for cluster of differentiation 34 
(CD34) and IGF‑II. Furthermore, partial hemorrhagic and 
necrotic findings, as well as high mitotic activity, suggested 
a malignant phenotype. The tumor was ultimately diagnosed 
as a malignant pelvic SFT with NICTH due to IGF‑II, and 
regular follow‑up CT scans and laboratory examinations were 
performed for 5 years, with no evidence of tumor recurrence 
or hypoglycemia, which were then discontinued at the patient's 
own prerogative.
Approximately 12 years later, the patient began to 
re‑experience episodes of loss of consciousness. Laboratory 
examinations revealed low blood glucose level (40 mg/dl), 
and an enhanced CT scan revealed a poorly-enhanced homo-
geneous tumor measuring ~90 mm in diameter, spreading 
within the pelvis. The tumor appeared to consist of 3 major 
components that were located ventrally to the sacral bone, 
immediately above the bladder and ventrally to the left 
common iliac artery (Fig. 1A and B). Pelvic SFT recurrence 
was suspected, and the patient was referred to the Depart-
ment of Urology, Tokyo Women's Medical University (Tokyo, 
Japan) on June 2014 for further evaluation and treatment. 
Endocrinological tests revealed that the levels of GH and 
IGF‑I were suppressed (GH, <0.03 ng/ml; IGF‑I, 27 ng/ml). 
An abdominal MRI scan showed a homogenous tumor with a 
low contrast-enhancement occupying the pelvis. T2-weighted 
images revealed a tumor that was iso- to hyper-intense with 
low diffusion (Fig. 1C and D), while the T1‑weighted images 
demonstrated that the tumor had clear margin. In addition, 
18F‑fluorodeoxyglucose (FDG)‑positron emission tomog-
raphy/CT was performed (Fig. 2). The maximal intensity 
projection image showed a moderate FDG uptake in the pelvic 
tumor (Fig. 2A). The maximum standardized uptake value was 
3.37 (Fig. 2B and D), 4.56 (Fig. 2B and D) and 4.16 (Fig. 2C) 
in each compartment of the tumor located ventral to the sacral 
bone, right above the bladder, and ventral to the left common 
iliac artery, respectively.
The tumor was diagnosed as a recurrent pelvic SFT and 
a second surgery was performed. Intraoperatively, the tumor 
was found to be fairly fragile and adhesive, and to have directly 
invaded the left ureter and perirectal fat tissue. The maximum 
amount of tumor possible was removed. The resected tumor 
tissue was immediately fixed with 20% formalin, embedded 
in paraffin, and subjected to histopathological diagnosis and 
immunohistochemistry. Paraffin sections (4‑µm‑thick) were 
stained with hematoxylin and eosin for routine histopathological 
diagnosis. Macroscopically, the tumor was grayish-white with 
prominent hemorrhage and necrosis (Fig. 3). Pathologically, 
the tumor revealed mild-sized spindle cells, densely arranged 
along a collagen background, with round and oval nuclei and a 
fine granular eosinophilic cytoplasm (Fig. 4A and B). 
For immunohistochemistry, the paraffin sections were 
stained using an autostainer (Ventana Medical Systems, Inc., 
Figure 1. CT and MRI scans. (A) Plain CT. (B) Contrast‑enhanced CT; arterial‑phase. (C) Plain MRI; T1‑weighted sequence. (D) Plain MRI; T2‑weighted 
sequence. The CT scan showed a huge homogenous tumor occupying the pelvis. The tumor exhibited little contrast enhancement, and consisted of 3 main 
components that were located ventrally to the sacral bone (~78x101x67 mm), immediately above the bladder (~85x99x62 mm) and ventrally to the left common 
iliac artery (~49x21x32 mm). The MRI scan revealed a mostly homogenous tumor in the pelvis with little contrast enhancement. CT, computed tomography; 
MRI, magnetic resonance imaging.
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Tucson, AZ, USA). Briefly, sections were deparaffinized 
in xylene, rehydrated in graded ethanol and immersed in 
0.3% hydrogen peroxide to quench the intrinsic peroxidase. 
Following incubation with normal sera of the animals in 
which the secondary antibodies were raised, antigen retrieval 
was performed by autoclaving the samples in Tris‑ethyl-
enediaminetetraacetic acid buffer (pH 9.0) in a pressure 
cooker. Subsequently, the samples were incubated with the 
following primary antibodies diluted 200‑fold: Anti‑B‑cell 
lymphoma 2 (bcl‑2) (clone 124; Dako, Glostrup, Denmark), 
Figure 2. FDG‑PET/CT findings. (A) The FDG PET/CT scan showed moderate FDG accumulation in the pelvic tumor on maximal intensity projection. 
(B) Axial PET/CT image. (C) Axial PET/CT image. (D) Sagittal PET/CT image. The maximum standard uptake values were (B and D; thin arrow) 3.37, 
(B and D; thick arrow) 4.56 and (C; arrowhead) 4.16 in the pelvic tumors located ventral to the sacral bone, right above the bladder,and ventral to the left 
common iliac artery, respectively. FDG, 18F‑fluorodeoxyglucose; PET, positron emission tomography; CT, computed tomography.
Figure 3. Macroscopic findings. (A) Gross specimen was generally fragile and prone to collapse. Sectioning revealed a grayish‑white mass with prominent 
(B) hemorrhaging and (C) necrosis. Surgical margins were largely ambiguous.
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anti‑CD34 (clone QBEnd 10; Dako) and anti‑IGF‑II (clone 
S1F2; Upstate Biotechnology, Inc., Lake Placid, NY, USA). 
Subsequently, the sections were rinsed with phosphate‑
buffered saline, and treated with biotinylated secondary 
antibodies and streptavidin-conjugated horseradish peroxi-
dase. The labeled antigens were visualized using Ventana 
Universal DAB kit (catalog no., 518‑100431; Ventana 
Medical Systems, Inc.), and the sections were counterstained 
with hematoxylin. The tumor cells were immunohisto-
logically positive for IGF‑II, CD34, bcl‑2 and vimentin, but 
negative for c-kit and S-100. The Ki-67 proliferative index 
was <5% (Fig. 4C‑E). Abnormal mitosis was mild and the 
Ki-67 proliferative index was low; however, according to two 
pathologists of the Department of Pathology, Tokyo Women’s 
Medical University, the tumor appeared to be malignant due 
to its hypercellularity, infiltrative growth, gross‑necrosis and 
cellular atypia. 
Western blot analysis was performed by the Department of 
Hypertension and Endocrinology of Tokyo Women's Medical 
University to investigate the preoperative heterogeneity of 
serum IGF‑II forms and the retention of IGF‑II postopera-
tively (Fig. 5). As shown in Fig. 5 (lane 2), the patient's serum 
contained the high molecular weight (HMW)‑form of IGF‑II. 
This result was similar to the results of other tumors secreting 
IGF‑II, obtained from previously studied patients (Fig. 5; 
lanes 5 and 6). HMW‑IGF‑II disappeared 4 days following 
the procedure, although several other bands appeared (Fig. 5; 
lane 3). At 13 days post‑surgery, the patient presented with 
rectal perforation, and a rectal resection and colostomy 
were immediately performed. Since the tumor was found to 
be adhesive and to have directly invaded the left ureter and 
perirectal fat tissue, long‑time and careful observations were 
required to ensure that no tumor traces remained after surgery. 
Thus, the patient was followed up by blood examination every 
Figure 5. Western blot analysis of serum IGF‑II. Western blot analysis 
revealed that the preoperative IGF‑II in the patient's serum was of the 
HMW‑form (lane 2), which is consistent with previously studied patients 
with non‑islet cell tumor hypoglycemia due to an IGF‑II producing tumor 
(lanes 5 and 6). Western blot analysis also showed that HMW‑IGF‑II disap-
peared 4 days after the procedure (lane 3), but several unidentified bands 
appeared. In a patient from the healthy control (lane 4), slight amounts of 
IGF‑II fat (7.5 kDa) were detected. IGF‑II, insulin‑like growth factor‑II; 
HMW, high-molecular-weight.
Figure 4. Immunohistochemical findings. Microscopic examinations revealed that the tumor was composed of mild‑sized spindle cells densely arranged on 
a collagen background, with round and oval nuclei and a fine granular eosinophilic cytoplasm; hematoxylin and eosin staining; magnification, (A) x40 and 
(B) x100). Immunohistochemical staining for (C) CD34 and (D) bcl‑2 showed diffuse positive staining. (E) Immunohistochemical staining for IGF‑II showed 
positive staining across the majority of the tumor cells. Immunoreactivity was also positive for vimentin and negative for c-kit and S-100. The Ki-67 prolifera-
tive index was <5% (data not shown). CD34, cluster of differentiation 34; bcl‑2, B‑cell lymphoma 2; IGF‑II, insulin‑like growth factor‑II.
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1 or 2 months, and by imaging examination such as CT every 
3 months. No tumor recurrence or hypoglycemic symptoms 
were observed on the follow‑up by blood examination every 
1 or 2 months and imaging examination, such as CT scan, 
every 3 months for 9 months after the surgery, and no further 
treatments were performed.
Discussion
Certain patients with SFTs experience frequent hypoglycemic 
episodes, which are associated with IGF‑II production. It has 
been reported that, while ~4% of pleural SFTs are associ-
ated with hypoglycemia, the incidence rate of hypoglycemia 
in retroperitoneal cases is ~11.5% (1,3,5). While high levels 
of IGF‑II are generally detected in the serum or tumor cells, 
Daughaday et al (6) reported an increase in the HMW form of 
IGF‑II in patients with NICTH. The screening and detection 
of suppressed IGF‑I levels and increased serum IGF‑II/IGF‑I 
ratios may serve as useful diagnostic markers (8). A defi-
ciency in functional GH could serve as a secondary marker 
for NICTH. Low IGF‑I levels in patients with NICTH are 
attributed to chronic attenuation of GH secretion, due to 
the negative feedback of IGF‑II (9). Several studies have 
shown that NICTH due to HMW‑IGF‑II can be diagnosed 
using western blot analysis (10‑12). Hata et al (10) examined 
HMW‑IGF‑II by using preoperative and postoperative blots 
and demonstrated that HMW‑IGF‑II disappeared postopera-
tively, which is considered to be a useful therapeutic index. In 
the present case, perioperative western blot analysis was also 
performed, which revealed the disappearance of HMW‑IGF‑II, 
but also the appearance of several unidentified protein bands. 
We speculated that this result may have been due to either 
hemolysis in the blood samples, artifacts caused by obtaining 
the postoperative sample too soon, or incomplete removal of 
the tumor.
Surgical removal is considered the gold standard for the 
treatment of SFTs (13,14). Resectability is the most impor-
tant factor influencing the outcome, and complete excision 
should allow for a favorable prognosis without recurrence 
or metastasis, even if the tumor is malignant (15). However, 
Baldi et al (7) reported a number of SFT cases that relapsed 
>10 years after initial diagnosis, despite a history of surgical 
excision of the primary tumor. Additionally, it is possible 
that certain inoperable cases are encountered, which are 
due to a poor general condition of the patient, metastasis 
or severe infiltration to other tissues and organs. Several 
studies have indicated that the length of time between the 
first and second recurrence is shorter compared with the 
time between the initial diagnosis and the first recurrence in 
frequently‑recurring SFTs, regardless of whether surgery was 
performed (7,10). Baldi et al (7) suggested that the inherent 
limitations of surgery may result in unavoidable recurrence 
or metastasis, since the anatomy of the retroperitoneum and 
pelvis make complete resection challenging. Thus, high rates 
of local failure could occur even for benign SFTs, due to 
incomplete removal. Frequent surgical resection for recurrent 
tumors causes aggressive adhesion, making complete surgical 
resection a considerable challenge. Furthermore, incomplete 
resection may actually cause tumor dissemination. These 
factors may explain why the time between the first and second 
recurrence is shorter. Thus, intraoperative findings and tumor 
location should be considered an associated risk for recurrence 
or metastasis in conjunction with pathological findings. In the 
present case, intraoperative findings and postoperative western 
blot analysis results indicated that a second recurrence will 
most likely occur more quickly than the first recurrence.
Although there are currently no consensus guidelines for 
curative treatments other than surgery, several previous studies 
have reported other effective treatments. Hosaka et al (16)
reported that a malignant pelvic IGF‑II‑secreting SFT was 
successfully treated via intra-arterial chemotherapy with 
cisplatin and carboplatin and concurrent radiotherapy for 
5 years. Although the patient had NICTH prior to treatment 
(as in the present case), hypoglycemic attacks were resolved 
in tandem with tumor shrinkage (16). Other studies reported 
that glucocorticoid therapy may be effective against hypogly-
cemia caused by IGF‑II‑producing tumors or tumor growth 
itself (11,17). Furthermore, several studies have suggested 
that imatinib mesylate is an effective therapy for unresect-
able SFTs (12,18,19). Yamada et al (20) reported that the 
Akt-mammalian target of rapamycin pathway is activated 
in ~50% of SFTs and is associated with the upregulation of 
receptor tyrosine kinases. Furthermore, sunitinib malate may 
be efficacious due to its anti‑platelet‑derived growth factor 
receptor-β activity (21). Recent genetic research revealed that 
the recurrent fusion of two genes, NGFI‑A binding protein 2 
and signal transducer and activator of transcription 6, both 
located at chromosomal region 12q31, was identified as 
a SFT‑specific chimeric fusion gene by next‑generation 
sequencing and reverse transcription polymerase chain reac-
tion (22‑24). Finally, the development of new‑generation drugs 
that target tumor-promoting genes or proteins is also essential. 
In the present case, intraoperative findings and western blot 
analysis results suggested that the resection of the tumor was 
incomplete, since the tumor was found to be adhesive and to 
have directly invaded the left ureter and perirectal fat tissue. 
Thus, adjuvant therapies such as the ones discussed, should 
be investigated in an effort to prevent recurrence, as current 
options do not appear to be effective.
In conclusion, the present study reports a rare case of 
malignant pelvic NICTH‑inducing SFT with IGF‑II secretion, 
which recurred ~12 years after the presumed complete resec-
tion of the primary tumor. The present case report suggested 
that the safe and complete resection of tumors may sometimes 
be challenging to perform, due to their adhesiveness or phys-
ical presentation; therefore, the indications for surgery should 
be considered with caution.
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